Clinical Report: CAP's New Guidelines for Amyloidosis Diagnosis

Overview

Revise to specify the types of variability in laboratory practices addressed by the guidelines.

Background

Amyloidosis is a rare but serious condition characterized by the accumulation of abnormal amyloid deposits, which can lead to significant morbidity. Accurate and early diagnosis is crucial for effective treatment, yet variability in laboratory methods has hindered consistent detection. The new CAP guidelines aim to provide a framework for standardized diagnostic practices across institutions.

Data Highlights

No numerical data available in the source material.

Key Findings

• The CAP guidelines recommend a standardized amyloid diagnostic panel validated across various specimen types.
• Fat pad fine-needle aspiration (FNA) is highlighted as a valuable first-line test for suspected systemic amyloidosis.
• Technical factors such as section thickness and staining optimization are critical for accurate amyloid detection.
• Negative results from surrogate biopsies should be interpreted cautiously, especially in the context of clinical suspicion.
• Mass spectrometry-based proteomics is recommended for superior accuracy in fibril protein typing.

Clinical Implications

Pathologists should adhere to the CAP guidelines to ensure reliable amyloid detection and characterization, which is essential for guiding therapy. Clinicians must remain vigilant in interpreting negative biopsy results in light of clinical findings to avoid misdiagnosis.

Conclusion

The CAP's new guidelines represent a significant step towards improving the diagnostic accuracy and standardization of amyloidosis detection, ultimately enhancing patient care.

References

1. College of American Pathologists, CAP Guidelines, 2025 -- Workup of Amyloidosis
2. Roswell Park Comprehensive Cancer Center, Video, 2023 -- When to Think of Amyloidosis, How to Diagnose and Treat
3. Acta Neuropathologica — Erratum: The Influence of Co-pathology on the Efficacy of Amyloid-Targeting Therapies: Clinical and Pathological Insights from Two Patients Treated with Aducanumab
4. Acta Neuropathologica — Erratum: The Role of Intraneuronal β‑CTF Fragment Aggregation in Inducing Aβ‑Independent Lysosomal-Autophagic Pathology
5. The ASCO Post — Amyloidosis: Pearls for Simplifying the Diagnosis AMYLOIDOSIS
6. Workup of Amyloidosis | College of American Pathologists
7. https://www.hematology.org/-/media/hematology/files/clinicians/guidelines/amyloidosis-guidelines-updated-2025/ash-diagnosis-of-amyloidosis-watermarked-pocket-guide-8-panel-0616-highrez.pdf
8. FDA grants traditional approval to daratumumab and hyaluronidase-fihj for newly diagnosed light chain amyloidosis | FDA